insights_auto
Why is RGEN down 2.98%?
Dive Deeperchevron_right
RGEN:NASDAQ
Repligen Corp
$162.24
arrow_downward
-2.98%(-4.98) 1D
Oct 8, 9:34:36 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RGEN...
Open
$163.83
High
$164.65
Low
$162.07
Mkt. cap
10.30B
Avg. vol.
1.15M
Volume
494.00
P/E ratio
221.15
52-wk high
$198.87
52-wk low
$100.99
EPS
$0.73
Beta
1.08
Shares outstanding
63.49M
No. of employees
2K
Open
$163.83
High
$164.65
Low
$162.07
Mkt. cap
10.30B
Avg. vol.
1.15M
Volume
494.00
P/E ratio
221.15
52-wk high
$198.87
52-wk low
$100.99
EPS
$0.73
Beta
1.08
Shares outstanding
63.49M
No. of employees
2K
News stories
From web sources and news partners
Stock Titan
·
21 hours ago
One holder reports no voting power in Repligen (RGEN), despite a 7.36M-share passive stake.
Investing.com UK
·
1 day ago
Form 4 Repligen Corporation For: 6 October By Investing.com
Simply Wall Street
·
2 days ago
RGEN: Cancer Vaccine Exposure And Bioprocess Expansion Support A Stronger Outlook
Profile
Repligen Corporation is an American life sciences company that develops and manufactures products used in biological drug manufacturing. The company is headquartered in Waltham, Massachusetts, and is listed on the Nasdaq under the symbol RGEN. Wikipedia
About Repligen Corp
CEOTony J. Hunt
Employees2K
Founded1981
HeadquartersWaltham, Massachusetts, United States
SectorHealth care
Websiterepligen.com